WaveMan
WaveMan · Company
PVLA · Palvella Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PVLA Palvella Therapeutics (PVLA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001583648
Quote by TradingView
Form 144 · 6
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
125
13F, latest reported quarter
Conversions, 180 days
14
Codes C/M, not in net · $262.8K priced

What the filings say about PVLA

Insiders, 180 days
-$11.2M net sold
3 sellers · 77% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$9.7M
6 notices

Palvella Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, PALVELLA THERAPEUTICS, INC. insiders sold a net $11.2M of stock across 69 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Goin Kathleen
Chief Operating Officer
SELL
2026-10-23 SECtraded 2026-10-21
2,043
$252.6K
n/a
Context
  • 33 earlier Form 4 trades (code P or S) here by this insider (33 sales), the last on Sep 16, 2026.
  • The trade is 90.0% of the 2,270 shares held after it.
  • 1 other insider sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Goin Kathleen sold about $252.6K of PVLA under a 10b5-1 plan on Oct 21, 2026; 1 other insider sold within 30 days and 125 funds added in the latest 13F quarter.
Goin Kathleen
Chief Operating Officer
SELL
2026-10-23 SECtraded 2026-10-21
1,663
$208.1K
n/a
Context
  • 33 earlier Form 4 trades (code P or S) here by this insider (33 sales), the last on Sep 16, 2026.
  • The trade is 274.0% of the 607 shares held after it.
  • 1 other insider sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Goin Kathleen sold about $208.1K of PVLA under a 10b5-1 plan on Oct 21, 2026; 1 other insider sold within 30 days and 125 funds added in the latest 13F quarter.
Goin Kathleen
Chief Operating Officer
SELL
2026-10-23 SECtraded 2026-10-21
607
$76.6K
n/a
Context
  • 33 earlier Form 4 trades (code P or S) here by this insider (33 sales), the last on Sep 16, 2026.
  • 1 other insider sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Goin Kathleen sold about $76.6K of PVLA under a 10b5-1 plan on Oct 21, 2026; 1 other insider sold within 30 days and 125 funds added in the latest 13F quarter.
JENKINS GEORGE M
Director
SELL
2026-10-14 SEC
476
$57.7K
-0.9%
Context
  • 25 earlier Form 4 trades (code P or S) here by this insider (5 buys, 20 sales), the last on Oct 13, 2026.
  • +27.0% median (+44.1% mean) 90-day return after 4 previous buys.
  • The trade is 0.3% of the 139,314 shares held after it.
  • 1 other insider sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director JENKINS GEORGE M sold about $57.7K of PVLA under a 10b5-1 plan on Oct 14, 2026; 1 other insider sold within 30 days and 125 funds added in the latest 13F quarter.
JENKINS GEORGE M
Director
SELL
2026-10-14 SEC
2,072
$254.1K
-0.9%
Context
  • 25 earlier Form 4 trades (code P or S) here by this insider (5 buys, 20 sales), the last on Oct 13, 2026.
  • +27.0% median (+44.1% mean) 90-day return after 4 previous buys.
  • The trade is 1.5% of the 137,242 shares held after it.
  • 1 other insider sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director JENKINS GEORGE M sold about $254.1K of PVLA under a 10b5-1 plan on Oct 14, 2026; 1 other insider sold within 30 days and 125 funds added in the latest 13F quarter.
69 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 64 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$11.2M over 180 days
-$9.6M over 90 days
below 85% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
125 funds bought in last quarter
more than 77% of Pharma & Biotech
Revenue
+52.0% year over year
more than 77% of Pharma & Biotech
Margin
-107.8% net margin
below 59% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
22.5% of the float short (float per yahoo 2026-10-27) · 9.8 days to cover · settled 2026-10-15
more than 89% of Pharma & Biotech
What changed in the last 30 days
Oct 23Chief Operating Officer Goin Kathleen sold $537.3K under a 10b5-1 plan (Oct 21)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 21Officer Goin Kathleen filed to sell $534.5K by Oct 21 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 14Director JENKINS GEORGE M sold $3.6M under a 10b5-1 plan (17 trades, Oct 12 to Oct 14)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 13Director JENKINS GEORGE M filed to sell $3.7M by Oct 13 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch PVLA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+77.0%12M
-1%+40%+81%+122%2025-102025-122026-022026-042026-062026-082026-10 2026-09-11 · JENKINS GEORGE M sold $982.0K2026-09-14 · JENKINS GEORGE M sold $937.0K2026-09-14 · JENKINS GEORGE M sold $853.0K2026-09-11 · JENKINS GEORGE M sold $694.4K2026-10-12 · JENKINS GEORGE M sold $675.7K2026-02-27 · JENKINS GEORGE M bought $500.0K2026-10-12 · JENKINS GEORGE M sold $447.6K2025-12-17 · Goin Kathleen sold $415.0K2026-05-20 · Goin Kathleen sold $371.1K2026-01-21 · Goin Kathleen sold $367.2K2026-10-12 · JENKINS GEORGE M sold $327.5K2026-10-14 · JENKINS GEORGE M sold $321.0K2026-08-19 · Goin Kathleen sold $303.3K2026-02-27 · HERON ELAINE J bought $300.0K2026-07-15 · Goin Kathleen sold $287.1K2026-03-18 · Goin Kathleen sold $266.6K2026-06-17 · Goin Kathleen sold $263.5K2026-10-13 · JENKINS GEORGE M sold $257.6K2026-10-14 · JENKINS GEORGE M sold $254.1K2026-09-16 · Goin Kathleen sold $253.5K2026-10-21 · Goin Kathleen sold $252.6K2026-09-16 · Goin Kathleen sold $250.8K2025-11-19 · Goin Kathleen sold $242.4K2026-02-18 · Goin Kathleen sold $239.5K2026-09-14 · JENKINS GEORGE M sold $238.8K2026-08-19 · Goin Kathleen sold $227.1K2026-10-13 · JENKINS GEORGE M sold $212.5K2026-06-17 · Goin Kathleen sold $210.0K2026-10-21 · Goin Kathleen sold $208.1K2026-03-18 · Goin Kathleen sold $204.8K2026-10-12 · JENKINS GEORGE M sold $196.1K2026-09-11 · JENKINS GEORGE M sold $195.0K2026-04-15 · Goin Kathleen sold $190.7K2026-04-15 · Goin Kathleen sold $189.2K2026-07-15 · Goin Kathleen sold $153.6K2026-09-16 · Goin Kathleen sold $150.7K2026-09-15 · JENKINS GEORGE M sold $142.5K2026-10-13 · JENKINS GEORGE M sold $136.1K2026-10-13 · JENKINS GEORGE M sold $129.2K2025-11-19 · Goin Kathleen sold $128.6K2026-07-15 · Goin Kathleen sold $124.7K2026-10-13 · JENKINS GEORGE M sold $123.3K2026-10-21 · Goin Kathleen filed to sell $534.5K2026-10-13 · JENKINS GEORGE M filed to sell $3.7M2026-09-16 · Goin Kathleen filed to sell $650.5K2026-09-11 · JENKINS GEORGE M filed to sell $4.1M2026-09-02 · CHRISTOPHER KIRITSY filed to sell $58.9K2026-08-19 · Goin Kathleen filed to sell $647.1K2026-07-15 · Goin Kathleen filed to sell $643.9K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PVLA: institutional holders (13F)

13F holdings, latest reported quarter
MONTANOVA CAPITAL, LLC
1,135,406 sh
$173.5M
JENNISON ASSOCIATES LLC
960,619 sh
$146.8M
BlackRock, Inc.
918,357 sh
$140.3M
Frazier Life Sciences Management, L.P.
882,400 sh
$134.8M
First Light Asset Management, LLC
771,901 sh
$118.0M

Congress trades in PVLA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PVLA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Goin Kathleen
Filed 2026-10-21
$534.5K
JENKINS GEORGE M
Filed 2026-10-13
$3.7M
Goin Kathleen
Filed 2026-09-16
$650.5K
JENKINS GEORGE M
Filed 2026-09-11
$4.1M
CHRISTOPHER KIRITSY
Filed 2026-09-02
$58.9K

PVLA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Eventide Healthcare & Life Sciences Fund
$35.4M position · as of 2026-06-30
2.0%
F/m Emerald Life Sciences Innovation ETF
$2.0M position · as of 2026-05-31
1.9%
Royce Smaller-Companies Growth Fund
$4.4M position · as of 2026-06-30
1.8%
PGIM Jennison Health Sciences Fund
$21.7M position · as of 2026-05-29
1.6%
AMG Frontier Small Cap Growth Fund
$1.4M position · as of 2026-07-31
1.5%
LISANTI SMALL CAP GROWTH FUND
$264.4K position · as of 2026-06-30
1.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 2
2 active
3
Phase 3
1 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $11.2M sold by insiders over 180 days, 125 funds added last quarter, $9.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PVLA financials

Revenue growth
+52.0%
XBRL, annual
Net margin
-107.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.4M
four quarters, 2023-10-01 to 2024-09-30
Net margin, TTM
-4,563%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$36.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-46.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-37.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-37.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-2.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/a$42.8M$25.9M
Operating income-$38.6M-$14.1M-$11.9M-$43.5M
Net income-$41.7M-$17.4M$18.7M-$33.3M
EPS (diluted)-3.71-7.832.17n/a
Operating cash flow-$25.0M-$10.8M-$13.7M-$59.9M
Cash$58.0M$83.6M$7.3M$38.6M
SEC XBRL, fiscal years, as known on 2026-10-28

PVLA Stock Sonar score 5/7 axes

Find similar shapesCompare

PVLA ranks highest on growth (77th percentile) and institutional and government (77th), and lowest on insider conviction (15th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
57
Inputs
  • Return on equity-46.6% · 56 pct, sector of 545
  • Return on assets-37.7% · 54 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-37.8% · 62 pct, sector of 576
Growth
77
Inputs
  • Revenue growth, YoY+52.0% · 77 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
15
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.6M · 30 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
77
Inputs
  • Funds adding, latest quarter125 · 77 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
29
Inputs
  • Short interest, % of float+22.5% · 10 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+11.0% · 48 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PVLA filings, in plain words

Are Palvella Therapeutics insiders buying or selling PVLA?

In the 180 days to 2026-10-28, Palvella Therapeutics insiders were net sellers, a net $11.2M across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of PVLA?

Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $9.7M of stock; the latest, by Goin Kathleen, was filed 2026-10-21.

Read the full summary

In the 180 days to 2026-10-28, Palvella Therapeutics insiders were net sellers of PVLA, a net $11.2M across purchases and sales reported on Form 4 by 3 sellers. 77% of the 48 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $9.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies